Monday’s Highlights at Noon: Dynavax (DVAX), TG Therapeutics (TGTX), Whiting Petroleum (WLL), Bluebird Bio (BLUE), Agios Pharma (AGIO)

So far Monday, December 9, NASDAQ is up 0.28% and the S&P is up 0.19%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Dynavax (DVAXResearch Report), TG Therapeutics (TGTXResearch Report), Whiting Petroleum (WLLResearch Report), Bluebird Bio (BLUEResearch Report) and Agios Pharma (AGIOResearch Report).

Dynavax is up 14.51% in midday trading to $6.52. Shares opened today at $5.69. The company has a 52-week low of $2.60 and a 52-week high of $12.42. On the Street’s front, the average 12-month analyst price target for the stock is $16.50, marking a 189.98% potential upside from current levels. In a report issued on December 3, William Blair analyst Matt Phipps maintained a Buy rating on DVAX.

TG Therapeutics is up 10.47% in midday trading to $8.89. Shares opened today at $8.05. The company has a 52-week low of $3.32 and a 52-week high of $9.73. On the Street’s front, the average 12-month analyst price target for the stock is $18.50, marking a 129.81% potential upside from current levels. In a report released today, H.C. Wainwright analyst Edward White reiterated a Buy rating on TGTX, with a price target of $20.00, which implies an upside of 148% from current levels.

Whiting Petroleum is up 9.27% in midday trading to $5.54. Shares opened today at $5.07. The company has a 52-week low of $4.29 and a 52-week high of $31.18. On the Street’s front, the average 12-month analyst price target for the stock is $8.36, marking a 64.89% potential upside from current levels. In a report issued on December 6, Barclays analyst William S. Thompson maintained a Hold rating on WLL, with a price target of $5.00, which represents a slight downside potential from current levels. Separately, on December 2, R. F. Lafferty’s Jaime Perez maintained a Buy rating on the stock and has a price target of $12.00. In the last 30 days, insiders have sold $3,019 worth of WLL shares.

See today’s analyst top recommended stocks >>

Bluebird Bio is down -8.83% in midday trading to $75.55. Shares opened today at $82.87. The company has a 52-week low of $71.42 and a 52-week high of $163.43. On the Street’s front, the average 12-month analyst price target for the stock is $116.63, marking a 40.74% potential upside from current levels. In a report released today, Stifel Nicolaus analyst Benjamin Burnett maintained a Hold rating on BLUE, with a price target of $96.00, which implies an upside of 16% from current levels. Separately, on the same day, Wells Fargo’s Jim Birchenough maintained a Buy rating on the stock and has a price target of $160.00.

Agios Pharma is down -8.28% in midday trading to $42.10. Shares opened today at $45.90. The company has a 52-week low of $28.36 and a 52-week high of $68.94. On the Street’s front, the average 12-month analyst price target for the stock is $59.86, marking a 30.41% potential upside from current levels. In a report released today, BMO analyst George Farmer maintained a Buy rating on AGIO, with a price target of $49.00, which represents a potential upside of 7% from where the stock is currently trading. Separately, on October 21, Goldman Sachs’ Salveen Richter maintained a Hold rating on the stock and has a price target of $40.00. In the last 30 days, insiders purchased $14M worth of AGIO shares. Over the last 3 months, the insider sentiment on Agios Pharma has been positive based on 30 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.